October 4, 2022
Loading...
You are here:  Home  >  Health Care & Life Science  -  Page 2
Latest

Sientra lowers guidance, shares drop 20%

By   /  Friday, August 12th, 2022  /  Banking & Finance, Earnings, Health Care & Life Science, Latest news, Subscriber content, Tri-County Public Companies  /  Comments Off on Sientra lowers guidance, shares drop 20%

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Latest

MannKind reports Q2 loss but beats revenue expectations

By   /  Friday, August 12th, 2022  /  Banking & Finance, Earnings, Health Care & Life Science, Latest news, Regions, Subscriber content, Top Stories, Tri-County Public Companies, Ventura County  /  Comments Off on MannKind reports Q2 loss but beats revenue expectations

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Latest

Atara announces plan to cut workforce by 20%

By   /  Tuesday, August 9th, 2022  /  Banking & Finance, Earnings, Health Care & Life Science, Latest news, left, Regions, Subscriber content, Top Stories, Tri-County Public Companies, Ventura County  /  Comments Off on Atara announces plan to cut workforce by 20%

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Latest

Inogen beats Q2 estimates, but shares still drop

By   /  Monday, August 8th, 2022  /  Banking & Finance, Earnings, Health Care & Life Science, Latest news, Regions, Santa Barbara County, Subscriber content, Top Stories, Tri-County Public Companies  /  Comments Off on Inogen beats Q2 estimates, but shares still drop

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Latest

Amgen beats analysts’ expectations for earnings and revenue in Q2

By   /  Thursday, August 4th, 2022  /  Banking & Finance, Earnings, Health Care & Life Science, Latest news, Regions, Subscriber content, Top Stories, Tri-County Public Companies, Ventura County  /  Comments Off on Amgen beats analysts’ expectations for earnings and revenue in Q2

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Latest

Amgen to buy ChemoCentryx for $3.7B

By   /  Thursday, August 4th, 2022  /  Banking & Finance, Health Care & Life Science, Latest news, left, Regions, Top Stories, Tri-County Public Companies, Ventura County  /  Comments Off on Amgen to buy ChemoCentryx for $3.7B

Amgen was having a relatively quiet year on the mergers and acquisitions front, at least until Aug. 4, when the Thousand Oaks-based biotech firm announced it will purchase ChemoCentryx for nearly $3.7 billion. ChemoCentryx is a Silicon Valley biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. It has Read More →

Latest

Arcutis to raise $150M in public stock offering

By   /  Wednesday, August 3rd, 2022  /  Banking & Finance, Health Care & Life Science, Latest news, Regions, Top Stories, Tri-County Public Companies, Ventura County  /  Comments Off on Arcutis to raise $150M in public stock offering

Arcutis Biotherapeutics, a Westlake Village-based company developing drugs for immune dermatological conditions, plans to raise $150 million through a public offering of additional shares of common stock. Arcutis announced the pricing of those shares on Aug. 2, at $20 per share. Shares of Arcutis closed at $19.50 that day and then shot up 17% on Read More →